Phaseline

Targets › GRB2

GRB2 (Growth factor receptor-bound protein 2): drug programs, companies and trials

2 programs from 1 company in 2 trials: 1 Phase 1, 1 Phase 2; Oncology; next expected readout Jul 2027.

Non-enzymatic adapter protein that plays a pivotal role in precisely regulated signaling cascades from cell surface receptors to cellular responses, including signaling transduction and gene expression. Thus, participates in many biological processes including regulation of innate and adaptive immunity, autophagy, DNA repair or necroptosis. (UniProt, P62993)

Open in Phaseline: the race on GRB2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bio-Path HoldingsBP1001
Liposomal Grb-2 antisense oligonucleotide (GRB2 mRNA inhibitor)
GRB2Phase 2Acute Myeloid Leukemia (AML)Dec 2027
Bio-Path HoldingsBP1001-A
Liposomal Grb2 antisense oligonucleotide
GRB2Phase 1Solid Tumor, AdultJul 2027

Conditions

Solid Tumor, Adult (1) Acute Myeloid Leukemia (AML) (1)

Modalities

other (1), small molecule (1)

Companies

Bio-Path Holdings (2)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.